AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26330052 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency topical agents
Number of subjects: 0
Study 26330052 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional differences in topical use
Number of subjects: 0
Study 25155203 — intervention group
Group type: EXPERIMENTAL
Intervention: Acromioplasty, tenotomy, and tendon suture (CR group, n=54)
Number of subjects: 103
Study 25155203 — intervention group
Group type: COMPARATOR
Intervention: Acromioplasty and tenotomy (AT group, n=49)
Number of subjects: 103
Study 25155203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon healing (CR group)
Number of subjects: 103
Study 25155203 — intervention group
Group type: COMPARATOR
Intervention: Acromioplasty and tenotomy (AT group)
Number of subjects: 103
Study 22192731 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus erlotinib (gemcitabine 1000 mg/m² on day 1, oxaliplatin 100 mg/m² on day 2, erlotinib 100 mg daily)
Number of subjects: 268
Study 22192731 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (gemcitabine 1000 mg/m² on day 1, oxaliplatin 100 mg/m² on day 2)
Number of subjects: 268
Study 22192731 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus erlotinib (for cholangiocarcinoma subgroup)
Number of subjects: 268
Study 22192731 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (for cholangiocarcinoma subgroup)
Number of subjects: 268
Study 22192731 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (overall survival)
Number of subjects: 268
Study 22192731 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 268
Study 22192731 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus erlotinib
Number of subjects: 268
Study 19880529 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic randomised controlled trials
Number of subjects: 4800
Study 19880529 — intervention group
Group type: EXPERIMENTAL
Intervention: Commuting to work by the trial team
Number of subjects: 4800
Study 19880529 — intervention group
Group type: EXPERIMENTAL
Intervention: Study centres' fuel use
Number of subjects: 4800
Study 19880529 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial team related travel
Number of subjects: 4800
Study 19880529 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant related travel
Number of subjects: 4800
Study 18250616 — intervention group
Group type: EXPERIMENTAL
Intervention: FREMS
Number of subjects: 20
Study 18250616 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 20
Study 16358997 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose rofecoxib combined with simvastatin
Number of subjects: 29
Study 16358997 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin alone
Number of subjects: 29
Study 16310019 — intervention group
Group type: EXPERIMENTAL
Intervention: BWLP+SC (behavioral weight loss program with stepped-care approach)
Number of subjects: 44
Study 16310019 — intervention group
Group type: EXPERIMENTAL
Intervention: BWLP+SC [PST] (behavioral weight loss program with stepped-care approach including problem-solving therapy)
Number of subjects: 44
Study 16310019 — intervention group
Group type: COMPARATOR
Intervention: BWLP (behavioral weight loss program without stepped-care approach)
Number of subjects: 44
Study 10371567 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-cancer screening intervention group (28,628 women offered screening)
Number of subjects: 54654
Study 10371567 — intervention group
Group type: COMPARATOR
Intervention: Control group (26,026 women)
Number of subjects: 54654
Study 10371567 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-cancer screening intervention group (after SES adjustment)
Number of subjects: 54654
Study 10371567 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-cancer screening intervention group (censoring deaths after diagnosis more than 3 years post-study)
Number of subjects: 54654
Study 10371567 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-cancer screening intervention group (younger than 50 years)
Number of subjects: 54654
Study 10371567 — intervention group
Group type: COMPARATOR
Intervention: Control group (other-cause mortality)
Number of subjects: 54654
Study 8701447 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical aids provided (average of three out of five advised)
Number of subjects: 83
Study 8701447 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical aids provided
Number of subjects: 83
Study 1992599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilutamide (300 mg/day) plus buserelin
Number of subjects: 248
Study 1992599 — intervention group
Group type: EXPERIMENTAL
Intervention: Castration plus nilutamide
Number of subjects: 248
Study 1992599 — intervention group
Group type: COMPARATOR
Intervention: Castration plus placebo
Number of subjects: 248
Study 6357890 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg intramuscular diclofenac sodium (Voltaren)
Number of subjects: 131
Study 6357890 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 131
Study 30831335 — intervention group
Group type: EXPERIMENTAL
Intervention: Focusing on one's own appearance (appearance group)
Number of subjects: 263
Study 30831335 — intervention group
Group type: COMPARATOR
Intervention: Writing about personality (personality group)
Number of subjects: 263
Study 30203750 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib therapy
Number of subjects: 180
Study 30203750 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium therapy
Number of subjects: 180
Study 26571037 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 60
Study 26571037 — intervention group
Group type: COMPARATOR
Intervention: 3% hypertonic saline (HS)
Number of subjects: 60
Study 25246338 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infusion of donor adipose-derived mesenchymal stem cells (AD-MSC) + hematopoietic stem cells (HSC)
Number of subjects: 285
Study 25246338 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cells (HSC)
Number of subjects: 285
Study 25246338 — intervention group
Group type: COMPARATOR
Intervention: No stem cell therapy (Control group)
Number of subjects: 285
Study 22504039 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM + MMRV
Number of subjects: 100
Study 22504039 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-CRM
Number of subjects: 100
Study 22504039 — intervention group
Group type: COMPARATOR
Intervention: MMRV
Number of subjects: 100
Study 20102716 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg, orally, 3 times daily)
Number of subjects: 335
Study 20102716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 17907108 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesaglitazar 1 mg
Number of subjects: 1707
Study 17907108 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesaglitazar
Number of subjects: 1707
Study 17907108 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesaglitazar and pioglitazone
Number of subjects: 1707
Study 16135350 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal motor response (group PROX)
Number of subjects: 150
Study 16135350 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal motor response (group DIST)
Number of subjects: 150
Study 11966970 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (active and passive jaw movement exercises, correction of body posture, relaxation techniques)
Number of subjects: 20
Study 11966970 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (no treatment)
Number of subjects: 20
Study 10194424 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim and cladribine
Number of subjects: 35
Study 10194424 — intervention group
Group type: COMPARATOR
Intervention: Cladribine alone
Number of subjects: 35
Study 7594322 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole plus low-dose amoxicillin
Number of subjects: 0
Study 7594322 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole monotherapy
Number of subjects: 0
Study 31743412 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrowhead Business Group (ABG) entrepreneurship education intervention; details on dosage and duration not available.
Number of subjects: 0
Study 31743412 — intervention group
Group type: COMPARATOR
Intervention: Comparison with other youth from the participating tribal community and state; details on intervention/control not available.
Number of subjects: 0
Study 30400355 — intervention group
Group type: EXPERIMENTAL
Intervention: North area dietary intake
Number of subjects: 6646
Study 30400355 — intervention group
Group type: EXPERIMENTAL
Intervention: North area nutrient intake
Number of subjects: 6646
Study 30400355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex, smoking status, and physical activity
Number of subjects: 6646
Study 26123678 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based smoking prevention programme 'Smoke-free Kids'
Number of subjects: 1398
Study 26123678 — intervention group
Group type: COMPARATOR
Intervention: Control condition (fact-based programme)
Number of subjects: 1398
Study 24184411 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic load breakfast
Number of subjects: 60
Study 24184411 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycaemic load breakfast
Number of subjects: 60
Study 24184411 — intervention group
Group type: EXPERIMENTAL
Intervention: Water breakfast
Number of subjects: 60
Study 24184411 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for age, IQ, BMI, waist circumference, and depression)
Number of subjects: 60
Study 22709245 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Interaction Guidance (VIG) for parents of premature infants
Number of subjects: 210
Study 22709245 — intervention group
Group type: COMPARATOR
Intervention: Care as usual for premature infants and their parents
Number of subjects: 210
Study 22709245 — intervention group
Group type: COMPARATOR
Intervention: Care as usual for full term infants and their parents
Number of subjects: 210
Study 19786967 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss programs (BWL)
Number of subjects: 298
Study 17531001 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 25
Study 17531001 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 with HAART
Number of subjects: 25
Study 17531001 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 25
Study 15511696 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (400 mg QD)
Number of subjects: 144
Study 15511696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 11578886 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical intubating position
Number of subjects: 20
Study 11578886 — intervention group
Group type: COMPARATOR
Intervention: Neutral position
Number of subjects: 20
Study 9569076 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (bicycle exercise and step aerobics) over a 6 week period
Number of subjects: 14
Study 9569076 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 14
Study 8036045 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate 40 mg/kg/day
Number of subjects: 14
Study 8036045 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate 25 mg/kg/day
Number of subjects: 14
Study 8036045 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (both dosages)
Number of subjects: 14
Study 2838288 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 238
Study 2838288 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with chemotherapy (RT-CT)
Number of subjects: 238
Study 31705746 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 60
Study 31705746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31705746 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 28470591 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised high-intensity interval training (HIT) for 8 weeks (3 × 10-min cycle-ergometer-HIT/week)
Number of subjects: 13
Study 28470591 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised high-intensity interval training (HIT) for 8 weeks (3 × 10-min cycle-ergometer-HIT/week)
Number of subjects: 13
Study 28470591 — intervention group
Group type: COMPARATOR
Intervention: Usual care for 8 weeks
Number of subjects: 13
Study 25766448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumin cyminum L. capsule (n = 26)
Number of subjects: 78
Study 25766448 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat120 capsule (n = 26)
Number of subjects: 78
Study 25766448 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 26)
Number of subjects: 78
Study 23289456 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused online interventions
Number of subjects: 0
Study 23289456 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-focused online interventions
Number of subjects: 0
Study 23289456 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined parent and child-focused online interventions
Number of subjects: 0
Study 23289456 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21653691 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus cisplatin (GP)
Number of subjects: 134
Study 21653691 — intervention group
Group type: EXPERIMENTAL
Intervention: gefitinib
Number of subjects: 134
Study 21653691 — intervention group
Group type: EXPERIMENTAL
Intervention: High tertile CFDNA group
Number of subjects: 134
Study 21653691 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma CFDNA
Number of subjects: 134
Study 18474492 — intervention group
Group type: EXPERIMENTAL
Intervention: ENF 180 mg qd
Number of subjects: 61
Study 18474492 — intervention group
Group type: COMPARATOR
Intervention: ENF 90 mg bid
Number of subjects: 61
Study 16401645 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg G115/0 mg glucose (ginseng)
Number of subjects: 27
Study 16401645 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 mg G115/25 g glucose (glucose)
Number of subjects: 27
Study 16401645 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg G115/25 g glucose (ginseng/glucose combination)
Number of subjects: 27
Study 16401645 — intervention group
Group type: COMPARATOR
Intervention: 0mg G115/0 mg glucose (placebo)
Number of subjects: 27
Study 12853380 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of slow-release clarithromycin
Number of subjects: 231
Study 12853380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 10961441 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin®
Number of subjects: 0
Study 8803506 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy occupational musculoskeletal loading
Number of subjects: 456
Study 8803506 — intervention group
Group type: EXPERIMENTAL
Intervention: High general occupational physical demands
Number of subjects: 456
Study 8803506 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity, aerobic power, or muscle strength characteristics
Number of subjects: 456
Study 1615189 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 65
Study 1615189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 6367466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin and ticarcillin (TT)
Number of subjects: 225
Study 6367466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin and ticarcillin plus cephalothin (TTC)
Number of subjects: 225
Study 6367466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin and mezlocillin (TM)
Number of subjects: 225
Study 31608447 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswellia serrata extract, curcumin, pine bark extract, methylsulfonylmethane (combined)
Number of subjects: 16
Study 31608447 — intervention group
Group type: COMPARATOR
Intervention: Boswellia serrata extract, curcumin, pine bark extract, methylsulfonylmethane (alone)
Number of subjects: 16
Study 29688845 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement intervention
Number of subjects: 2700
Study 29688845 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard immunization program)
Number of subjects: 2700
Study 27121185 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect school with script analysis
Number of subjects: 64
Study 27121185 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic body awareness treatment
Number of subjects: 64
Study 27121185 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 64
Study 25014001 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10‐20 mg/d)
Number of subjects: 141
Study 25014001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 22513879 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 120
Study 22513879 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid injections
Number of subjects: 120
Study 19915909 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate generation of the allocation sequence
Number of subjects: 64
Study 19915909 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate allocation concealment
Number of subjects: 64
Study 19915909 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate blinding
Number of subjects: 64
Study 19915909 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate sample size calculation
Number of subjects: 64
Study 19915909 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of funding source
Number of subjects: 64
Study 18853315 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lomefloxacin 0.3%
Number of subjects: 79
Study 18853315 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol 0.2% with polymyxin B 2500 U/ml
Number of subjects: 79
Study 15339466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fufang Sishen Decoction (FFSSD), 6 g, b.i.d.
Number of subjects: 102
Study 15339466 — intervention group
Group type: COMPARATOR
Intervention: Propafenone, 150 mg, q 8 h
Number of subjects: 102
Study 11145620 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct access service for laparoscopic sterilization
Number of subjects: 232
Study 11145620 — intervention group
Group type: COMPARATOR
Intervention: Routine referral (Control)
Number of subjects: 232
Study 9647301 — intervention group
Group type: EXPERIMENTAL
Intervention: Serologically unconfirmed symptomatic URTI
Number of subjects: 0
Study 9647301 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised antiviral antibody titres
Number of subjects: 0
Study 9647301 — intervention group
Group type: COMPARATOR
Intervention: Control group (not at risk)
Number of subjects: 0
Study 9647301 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic or serologically defined at risk periods
Number of subjects: 0
Study 7954995 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms.kg‐1
Number of subjects: 100
Study 7954995 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1
Number of subjects: 100
Study 7954995 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 60 micrograms.kg‐1
Number of subjects: 100
Study 7954995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study 2678834 — intervention group
Group type: EXPERIMENTAL
Intervention: DDP alone
Number of subjects: 135
Study 2678834 — intervention group
Group type: EXPERIMENTAL
Intervention: DDP in combination with adriamycin (ADM) and cyclophosphamide
Number of subjects: 135
Study 323994 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate
Number of subjects: 0
Study 323994 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofenate
Number of subjects: 0
Study 323994 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29475854 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation of major salivary glands with saline
Number of subjects: 49
Study 29475854 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation of major salivary glands with saline followed by triamcinolone acetonide (TA) in saline
Number of subjects: 49
Study 29475854 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study 26860808 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed (25 g daily)
Number of subjects: 159
Study 26860808 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitex agnus (3.2‐4.8 mg daily)
Number of subjects: 159
Study 26860808 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo for both)
Number of subjects: 159
Study 24225451 — intervention group
Group type: COMPARATOR
Intervention: MNP (Micronutrient Powder)
Number of subjects: 19
Study 24225451 — intervention group
Group type: EXPERIMENTAL
Intervention: MNP+Zn (Micronutrient Powder with 10 mg of zinc)
Number of subjects: 19
Study 22431798 — intervention group
Group type: EXPERIMENTAL
Intervention: WC2031 (doxycycline hyclate delayed-release 200-mg tablet) orally once daily for 7 days
Number of subjects: 495
Study 22431798 — intervention group
Group type: COMPARATOR
Intervention: Vibramycin (doxycycline hyclate capsule) 100 mg orally twice daily for 7 days
Number of subjects: 495
Study 22431798 — intervention group
Group type: EXPERIMENTAL
Intervention: WC2031
Number of subjects: 495
Study 22431798 — intervention group
Group type: COMPARATOR
Intervention: Vibramycin
Number of subjects: 495
Study 20385634 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated video
Number of subjects: 0
Study 20385634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet
Number of subjects: 0
Study 20385634 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18705027 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium extended-release 250 mg once daily
Number of subjects: 300
Study 18705027 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium extended-release 500 mg once daily
Number of subjects: 300
Study 18705027 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium extended-release 1000 mg once daily
Number of subjects: 300
Study 18705027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300